Nationwide Fund Advisors Continues to Hold Stake in Puma Biotechnology Inc (PBYI)

Nationwide Fund Advisors continued to hold its position in shares of Puma Biotechnology Inc (NYSE:PBYI) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,222 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Nationwide Fund Advisors’ holdings in Puma Biotechnology were worth $1,418,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PBYI. Franklin Resources Inc. purchased a new stake in shares of Puma Biotechnology during the 2nd quarter valued at approximately $50,134,000. Renaissance Technologies LLC purchased a new stake in shares of Puma Biotechnology during the 1st quarter valued at approximately $7,682,000. Vanguard Group Inc. raised its position in shares of Puma Biotechnology by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares during the period. Marshall Wace North America L.P. purchased a new stake in shares of Puma Biotechnology during the 1st quarter valued at approximately $3,481,000. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in shares of Puma Biotechnology during the 1st quarter valued at approximately $3,481,000. 80.98% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Puma Biotechnology Inc (NYSE PBYI) opened at 121.60 on Friday. The company has a 50-day moving average of $111.89 and a 200 day moving average of $79.30. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $127.02. The firm’s market cap is $4.52 billion.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.32) by ($0.78). Equities research analysts anticipate that Puma Biotechnology Inc will post ($8.69) earnings per share for the current fiscal year.

Several research firms have recently commented on PBYI. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Citigroup Inc. reiterated a “buy” rating and issued a $114.00 target price on shares of Puma Biotechnology in a report on Tuesday, July 18th. Stifel Nicolaus reiterated a “buy” rating and issued a $118.00 target price (up previously from $105.00) on shares of Puma Biotechnology in a report on Tuesday, July 18th. Leerink Swann reiterated an “outperform” rating and issued a $125.00 target price on shares of Puma Biotechnology in a report on Wednesday, August 2nd. Finally, BidaskClub upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $124.89.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 22.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Nationwide Fund Advisors Continues to Hold Stake in Puma Biotechnology Inc (PBYI)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/10/20/nationwide-fund-advisors-continues-to-hold-stake-in-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply